Skip to main content

Atrium Therapeutics, Inc.

corporate_fare Company Profile

Atrium Therapeutics, Inc.

RNA·NASDAQ·Life Sciences·CIK 0002093101

Atrium Therapeutics, Inc. is a biopharmaceutical company that develops RNA-based therapies specifically for heart conditions, aiming to change how cardiomyopathies are treated. The company's current product candidates in development include ATR 1072, which is a siRNA-based therapy designed to target PRKAG2 for the treatment of PRKAG2 syndrome. Another candidate is ATR 1086, also a siRNA-based therapy, which targets PLN for the treatment of PLN cardiomyopathy. Atrium Therapeutics also has a broader pipeline focused on treating various genetic and cardiac diseases. The company was incorporated in 2025 and operates from its headquarters in San Diego, California.

Atrium Therapeutics, Inc. (NASDAQ:RNA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for RNA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Avidity Biosciences Files Proxy Materials for Novartis Merger and Spin-Off of Cardiology Assets
$6.92
52-week range · as of 2026-10-08 $6.92 – $16.77
Market cap
$149.27M
Volume
319.7K (1.4× avg)
3-mo avg 228.9K
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RNA - Filings & News (Page 2)

RNA
Jan 12, 2026, 4:30 PM EST
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $72.35
Real-time Price: $6.92 info
Change: -$65.43 (-90%) info
Market Cap: $149.275M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets